21 CFR 528.2001
§ 528.2001
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 528.2001, § 528.2001, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87678
- Permanent ID
ys:prov:87678@1- SHA-256
af0f98530def6b41ab7aacea7d9c57e976f68f730831f2a9dc19ac735435aae4
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specifications. pPL657 in the glycoprotein galactosyltransferase alpha-1,3 (GGTA1) gene in domestic pigs.
(b) Sponsor. See No. 086134 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Intended use. pPL657 rDNA construct in the glycoprotein galactosyltransferase alpha-1,3 gene (GGTA1) in the lineage of domestic pigs (Sus scrofa domesticus) hemizygous and homozygous for the intentional genomic alteration resulting in undetectable endogenous galactose alpha-1,3-galactose sugar residues on biological derivatives of domestic pigs homozygous for the intentional genomic alteration lineage that are intended to be used as sources of food or human therapeutics including excipients, devices, drugs, or biological products.
(2) Limitations. Pigs of this lineage (possessing the intentional genomic alteration (pPL657 rDNA construct)) should not be treated with aminoglycoside drugs and must only be housed in physically contained facilities specified in the approved application.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.